Allergopharma
The allergy and specific immunotherapy specialist

Allergopharma is an internationally operating pharmaceutical company specialized in research, production and distribution of preparations for in vivo diagnosis and treatment - specific immunotherapy (SIT) - of type 1 allergies.

Allergies caused by grass pollen, tree pollen (e.g. birch pollen), house dust mite allergens or mould spores are now among the most prevalent of all diseases and affect 20-35% of people worldwide. Subcutaneous specific immunotherapy (SCIT) is widely accepted as the only causal treatment for allergies that can prevent the allergic march to asthma and new allergies/ sensitizations (long-term efficacy). ...read more

Change in leadership at Allergopharma

After 43 years as CEO of Allergopharma Mr. Joachim Ganzer has left the company at the end of 2012 and went into retirement. Mrs. Uta Kemmerich-Keil succeeds him as CEO ... more

SCIT with pollen preparations is effective and safe₍₁₎

A total of 221 office-based allergologists in Germany participated in this prospec-tive observational multi-centre study. They docu-mented data ... more

"Allergy Living and Learning" - an European Initiative

The Allergy Living and Learning initiative was performed in 10 European countries by means of a specific questionnaire to investigate patients' ... more

New publication on subcutaneous immunotherapy

New publication on subcutaneous immuno-therapy (SCIT) by Dominicus et al. published in European Annals of Allergy ... more

Allergopharma continuously contributes largely to the promotion of the sciences in Europe in the areas allergology and immunology. The range of support reaches from memberships in organizations and institutions over project cooperations to significant financial engagements.

Print page

AllergopharmaThe allergy and specific immunotherapy specialist